Biomarkers. Screening for C-reactive protein in CVD prediction

Sanne A E Peters; Frank L J Visseren; Diederick E Grobbee

doi:10.1038/nrcardio.2012.164

Biomarkers. Screening for C-reactive protein in CVD prediction

Nat Rev Cardiol. 2013 Jan;10(1):12-4. doi: 10.1038/nrcardio.2012.164. Epub 2012 Nov 20.

Authors

Sanne A E Peters¹, Frank L J Visseren, Diederick E Grobbee

Affiliation

¹ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Stratenum 6.131, Heidelberglaan 100, Utrecht, The Netherlands. s.a.e.peters@umcutrecht.nl

PMID: 23165068
DOI: 10.1038/nrcardio.2012.164

Abstract

Adding C-reactive protein (CRP) level to conventional cardiovascular risk models has been suggested to improve risk prediction for cardiovascular events. However, evaluation of the potential impact of CRP measurement in cardiovascular risk management will require studies designed to quantify the effect of additional CRP assessment on medical decision-making, patient outcomes, and cost-effectiveness.

MeSH terms

Biomarkers / blood
C-Reactive Protein / analysis*
Cardiovascular Diseases / blood
Cardiovascular Diseases / etiology*
Cardiovascular Diseases / prevention & control
Decision Support Techniques
Humans
Inflammation Mediators / blood*
Mass Screening / methods*
Predictive Value of Tests
Prognosis
Risk Assessment
Risk Factors

Substances

Biomarkers
Inflammation Mediators
C-Reactive Protein